NCT02541383: Phase 3 - Bortezomib, thalidomide, dex +/-Daratumumab before & after ASCT (CASSIOPEIA)
NCT02519452: Phase 1 - Daratumumab + Recombinant Human Hyaluronidase (rHuPH20) RRMM - PAVO Study
NCT02076009: Phase 3 - Daratumumab, Lenalidomide & Dex (DRd) VS Len & Dexa (Rd) - MMY3003 (POLLUX)
NCT02195479 : A Phase 3, Study of Bortezomib, Melphalan, Prednisone & Daratumumab ALCYONE trial
NCT02252172 : Phase 3 - Dara, Lena & Dex VS Len & Dex in previously untreated Myeloma - MAIA STUDY
NCT02316106: Phase 2 - A Study to Evaluate 3 Dose Schedules of Daratumumab in SMM - CENTAURUS
NCT02136134: Phase 3 - Daratumumab Plus Bortezomib & Dexa in relapsed Myeloma MMY3004 (CASTOR) Study
NCT01985126: Phase 2 - Dara in MM who had 3 prior lines inc. PI, Imid - or db. ref. MMY2002 (SIRIUS)
NCT01998971: Phase 1 - JNJ-54767414 (HuMax CD38) (Anti-CD38 Mono. Ab. ) in Myeloma EQUULEUS; MMY1001
NCT01916252: Phase 3 - Bortezomib, Lenalidomide & IV Busulfan Under 65 - (GEM2012MENOS65) PETHEMA
NCT01592370: Phase 1/2: Safety and Effectiveness of Nivolumab and Daratumumab in Multiple Myeloma
NCT01191060: Phase 3 - IFM 2009 - (IFM/DFCI2009) Conventional dose RVD to High-Dose + ASCT -NDMM
NCT00833560: Phase 2: A Study of Bortezomib, Cyclophosphamide, and Dexamethasone in Patients NDMM
NCT00722566: Phase 3: A Study of Subcutaneous and Intravenous VELCADE in Patients With RRMM
NCT00507442: Phase 1/2 Study of VELCADE® in Combination With Other Drugs to Treat NDMM EVOLUTION
NCT00574288: Phase 1/2: Daratumumab (HuMax®-CD38) Safety Study in Multiple Myeloma - GEN501 study
NCT00111319: Phase 3 : VELCADE/Melphalan/Prednisone Versus Melphalan/Prednisone in NDMM